Last edition
News about "chronic diseases"
Lilly Completes Acquisition of Morphic
Morphic is a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Chronic Diseases | 17/08/2024 | By Aishwarya | 126
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members